171 related articles for article (PubMed ID: 29140422)
1. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
[TBL] [Abstract][Full Text] [Related]
2. Improved survival in metastatic germ-cell cancer.
Fankhauser CD; Sander S; Roth L; Beyer J; Hermanns T
Ann Oncol; 2018 Feb; 29(2):347-351. PubMed ID: 29161363
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
4. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.
Adra N; Althouse SK; Liu H; Brames MJ; Hanna NH; Einhorn LH; Albany C
Ann Oncol; 2016 May; 27(5):875-9. PubMed ID: 26861605
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil.
Vasconcellos VF; Bastos DA; Pereira AAL; Watarai GY; Pereira BR; de Godoy A; Almeida-Silva J; Muniz DQB; Guglielmetti GB; Nahas WC; Dzik C
J Glob Oncol; 2019 Feb; 5():1-8. PubMed ID: 30779600
[TBL] [Abstract][Full Text] [Related]
8. Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT).
Taza F; Abonour R; Zaid MA; Althouse SK; Anouti B; Akel R; Hanna NH; Adra N; Einhorn LH
Clin Genitourin Cancer; 2023 Apr; 21(2):213-220. PubMed ID: 36737276
[TBL] [Abstract][Full Text] [Related]
9. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.
Antonelli L; Ardizzone D; Ravi P; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Fizazi K; King JM; Adra N; Douglawi A; Cary C; Sweeney C; Fankhauser CD
Eur J Cancer; 2023 Mar; 182():144-154. PubMed ID: 36787661
[TBL] [Abstract][Full Text] [Related]
10. A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancer.
Incesu RB; Morra S; Scheipner L; Barletta F; Baudo A; Garcia CC; Tappero S; Piccinelli ML; Tian Z; Saad F; Shariat SF; de Cobelli O; Terrone C; Chun FKH; Carmignani L; Briganti A; Ahyai S; Longo N; Tilki D; Graefen M; Karakiewicz PI
Jpn J Clin Oncol; 2024 May; 54(5):592-598. PubMed ID: 38369557
[TBL] [Abstract][Full Text] [Related]
11. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
Shamash J; Mee M; Sarker SJ; Wilson P; Ansell W; Greenwood M; Berney D; Alifrangis C
BJU Int; 2020 Jun; 125(6):843-852. PubMed ID: 31688976
[TBL] [Abstract][Full Text] [Related]
12. Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Bokemeyer C
Eur J Cancer; 2018 May; 94():16-25. PubMed ID: 29505967
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
[TBL] [Abstract][Full Text] [Related]
14. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.
Raggi D; Mariani L; Giannatempo P; Lo Vullo S; Giardiello D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Calareso G; Magni M; Di Nicola M; Verzoni E; Grassi P; Procopio G; De Braud F; Pizzocaro G; Salvioni R; Necchi A
Urol Oncol; 2015 Jul; 33(7):332.e19-24. PubMed ID: 25985712
[TBL] [Abstract][Full Text] [Related]
15. Factors that impact the outcomes in testicular germ cell tumors in low-middle-income countries.
Saju SV; Radhakrishnan V; Ganesan TS; Dhanushkodi M; Raja A; Selvaluxmy G; Sagar TG
Med Oncol; 2019 Feb; 36(3):28. PubMed ID: 30725328
[TBL] [Abstract][Full Text] [Related]
16. Bleomycin, etoposide and cisplatinum (BEP) chemotherapy for metastatic germ cell tumours: treatment outcomes at UKM medical centre, Malaysia.
Azrif M; Leong YK; Aslan NM; Fong KV; Ismail F
Asian Pac J Cancer Prev; 2012; 13(6):2467-71. PubMed ID: 22938405
[TBL] [Abstract][Full Text] [Related]
17. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
[TBL] [Abstract][Full Text] [Related]
18. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
Lorch A; Bascoul-Mollevi C; Kramar A; Einhorn L; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin K; Lotz JP; Germà-Lluch JR; Powles T; Kollmannsberger C; Beyer J
J Clin Oncol; 2011 Jun; 29(16):2178-84. PubMed ID: 21444870
[TBL] [Abstract][Full Text] [Related]
19. Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor.
King JM; Althouse S; Cary C; Masterson T; Foster RS; Ashkar R; Hanna NH; Einhorn LH; Adra N
J Urol; 2022 Sep; 208(3):641-649. PubMed ID: 35674780
[TBL] [Abstract][Full Text] [Related]
20. Multimodality treatment outcome in patients with primary malignant mediastinal germ cell tumor in adults.
Biswas B; Dabkara D; Sengupta M; Ganguly S; Ghosh J; Arunsingh S M; Sen S
Cancer Rep (Hoboken); 2021 Feb; 4(1):e1306. PubMed ID: 33029924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
